China NMPA Accepts Ocumension's NDA for Glaucoma Drug OT-301
核心洞察
China's National Medical Products Administration (搜索) has accepted Ocumension Therapeutics (搜索)' new drug application for OT-301, an ophthalmic solution for open-angle glaucoma (搜索) and ocular hypertension (搜索).
The filing is supported by the Mont Blanc and Denali phase III trials, with Mont Blanc completed in the U.S. and China in 2022.
The Denali multi-regional phase III study met its primary endpoint of non-inferiority to latanoprost in August 2025, though approval and commercial success are not guaranteed.
China's National Medical Products Administration (搜索) has accepted the new drug application from Ocumension Therapeutics (搜索) for OT-301, an ophthalmic solution intended to lower intraocular pressure in patients with open-angle glaucoma (搜索) or ocular hypertension (搜索).
The filing is supported by two phase III trials. The Mont Blanc trial, completed in the U.S. and China in 2022, demonstrated efficacy and safety, while the multi-regional Denali phase III study met its primary endpoint of non-inferiority to the current standard of care, latanoprost, in August 2025.
Ocumension describes OT-301 as a key pipeline asset that could strengthen its competitive position in the regional ophthalmology market if commercialized. The company cautions that there is no guarantee of ultimate market approval or commercial success.